Monday - May 5, 2025
Kalamazoo, Michigan, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for third quarter of fiscal year 2023 on Thursday, November 2, 2023. A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s third quarter of fiscal year 2023, that ended September 30, 2023.
Stryker will host a webcast at 4:30pm ET on Thursday, November 2, 2023, to discuss results for its third quarter fiscal year 2023. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's website two hours after the live call ends.
About Stryker
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or jason.beach@stryker.com
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or yin.becker@stryker.com
Last Trade: | US$378.22 |
Daily Change: | 4.23 1.13 |
Daily Volume: | 3,684,668 |
Market Cap: | US$144.190B |
May 01, 2025 March 04, 2025 March 03, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load